iRegene Therapeutics
PrivateLast Round
Series C
Extension
Jul 2, 2026
Total Funding Raised
$170.7M
Company Overview
iRegene Therapeutics operates in Healthcare & Life Sciences and is based in Wuhan. Its latest recorded funding round was a Series C Extension round in July 2026.
iRegene Therapeutics is a biotechnology company that develops chemically induced allogeneic cell therapies for the treatment of degenerative diseases such as Parkinson's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iRegene Therapeutics Comparables
Compare iRegene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XellSmart | 88% | |
| Kenai Therapeutics | 85% | |
| Hopstem Biotechnology | 82% |
For institutional investors. Book with your work email.
iRegene Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jul 2, 2026 | ||||
| Series C | Jun 1, 2026 | ||||
| Series B | Sep 4, 2025 | ||||
| Series B Extension | Apr 11, 2025 | ||||
| Series B | Oct 13, 2024 | ||||
Series A Extension | Jan 24, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
iRegene Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ceyuan Ventures | Series B |
| Shanghai Guosheng Capital Management Co., Ltd. | Series B |
| China Capital Management Co., Ltd. | Series C Extension |
| Shenzhen New Industry Venture Capital | VC Round |
| Northern Light Venture Capital | Series B |
| Hony Capital | Series C Extension |
| Shenzhen Dachen Caizhi Venture Capital Management | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Monthly visitors grew 386% MoM to 525.
- Sep 4, 2025
$42.1M round led by Northern Light Venture Capital.
For institutional investors. Book with your work email.
iRegene Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about iRegene Therapeutics's valuation, stock price, and market status.
Is iRegene Therapeutics a public or private company?
iRegene Therapeutics is a private company.
What is the current stock price of iRegene Therapeutics?
iRegene Therapeutics is a private company, so its shares have no public market price. Caplight tracks iRegene Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is iRegene Therapeutics worth (valuation)?
Valuation information for iRegene Therapeutics is not publicly available.
Can I buy iRegene Therapeutics stock?
iRegene Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was iRegene Therapeutics's last funding round?
iRegene Therapeutics's most recent funding round was Series C Extension on July 2, 2026.
Who are the main investors in iRegene Therapeutics?
Key investors in iRegene Therapeutics include Ceyuan Ventures, Shanghai Guosheng Capital Management Co., Ltd., Northern Light Venture Capital, Shenzhen Dachen Caizhi Venture Capital Management.
Will iRegene Therapeutics IPO soon?
No public IPO plans have been announced for iRegene Therapeutics.
How can I track iRegene Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in iRegene Therapeutics's shares on secondary markets.